Advertisement

Incidence of risk factors for developing hyperkalemia when using ACE inhibitors in cardiovascular diseases

  • Omalhassan Amir
  • Yahaya HassanEmail author
  • Azmi Sarriff
  • Ahmed Awaisu
  • Noorizan Abd. Aziz
  • Omar Ismail
Research Article

Abstract

Study objective To determine the incidence of and the risk factors associated with hyperkalemia, induced by ACEI–drug interactions among cardiac patients. Setting Five medical and cardiology wards of a tertiary care center in Malaysia. Subjects Five hundred cardiac inpatients, who received ACEIs concomitantly with other interacting drugs. Method This was a prospective cohort study of 500 patients with cardiovascular diseases admitted to Penang Hospital between January to August 2006, who received ACEIs concomitantly with other interacting drugs. ACEI–drug interactions of clinical significance were identified using available drug information resources. Drug Interaction Probability Scale (DIPS) was used to assess the causality of association between ACEI–drug interactions and the adverse outcome (hyperkalemia). Main outcome measure Hyperkalemia as an adverse clinical outcome of the interaction was identified from laboratory investigations. Results Of the 489 patients included in the analysis, 48 (9.8%) had hyperkalemia thought to be associated with ACEI–drug interactions. Univariate analysis using binary logistic regression revealed that advanced age (60 years or more), and taking more than 15 medications were independent risk factors significantly associated with hyperkalemia. However, current and previous smoking history appeared to be a protective factor. Risk factors identified as predictors of hyperkalemia secondary to ACEI–drug interactions by multi-logistic regression were: advanced age (adjusted OR 2.3, CI 1.07–5.01); renal disease (adjusted OR 4.7, CI 2.37–9.39); hepatic disease (adjusted OR 5.2, CI 1.08–25.03); taking 15–20 medications (adjusted OR 4.4, CI 2.08–9.19); and taking 21–26 medications (adjusted OR 9.0, CI 1.64–49.74). Conclusion Cardiac patients receiving ACEIs concomitantly with potentially interacting drugs are at high risk of experiencing hyperkalemia. Old age, renal disease, hepatic disease, and receiving large number of medications are factors that may significantly increase their vulnerability towards this adverse outcome; thus, frequent monitoring is advocated.

Keywords

ACE-inhibitors Drug–drug interactions Hyperkalemia Incidence Risk factors 

Notes

Acknowledgments

We thank the Ministry of Health, Khartoum State, Sudan for awarding the scholarship for this research. We also thank the Khartoum Medical Insurance Services Corporation, Khartoum State and the staff of pharmacy department, medical and cardiology wards at Penang Hospital, Malaysia for their cooperation.

Funding

None.

Conflicts of interest

None to declare.

References

  1. 1.
    Sica DA. Angiotensin-converting enzyme inhibitors side effects: physiologic and non-physiologic considerations. J Clin Hypertens. 2004;6(7):410–6. doi: 10.1111/j.1524-6175.2004.02866.x.CrossRefGoogle Scholar
  2. 2.
    Perazella MA, Mahnensmith RL. Hyperkalemia in the elderly drugs exacerbate impaired potassium homeostasis. J Gen Intern Med. 1997;12(10):646–56. doi: 10.1046/j.1525-1497.1997.07128.x.PubMedCrossRefGoogle Scholar
  3. 3.
    Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med. 2000;160(5):685–93. doi: 10.1001/archinte.160.5.685.PubMedCrossRefGoogle Scholar
  4. 4.
    Cruz CS, Cruz AA, Marcilio de Souza CA. Hyperkalaemia in congestive heart failure patients using ACE inhibitors and spironolactone. Nephrol Dial Transplant. 2003;18(9):1814–9. doi: 10.1093/ndt/gfg295.PubMedCrossRefGoogle Scholar
  5. 5.
    RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the randomized aldactone evaluation study, RALES). Am J Cardiol. 1996;78(6):902–7.Google Scholar
  6. 6.
    Anton C, Cox AR, Watson RDS, Ferner RE. The safety of spironolactone treatment in patients with heart failure. J Clin Pharm Ther. 2003;28(4):285–7. doi: 10.1046/j.1365-2710.2003.00491.x.PubMedCrossRefGoogle Scholar
  7. 7.
    Palmer B. Managing hyperkalemia caused by inhibitors of the renin–angiotensin–aldosterone system. N Engl J Med. 2004;351(6):585–92. doi: 10.1056/NEJMra035279.PubMedCrossRefGoogle Scholar
  8. 8.
    Saito M, Takada M, Hirooka K, Isobe F, Yasumura Y. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil. J Clin Pharm Ther. 2005;30(6):603–10. doi: 10.1111/j.1365-2710.2005.00694.x.PubMedCrossRefGoogle Scholar
  9. 9.
    Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med. 2004;351(6):543–51. doi: 10.1056/NEJMoa040135.PubMedCrossRefGoogle Scholar
  10. 10.
    Wrenger E, Muller R, Moesenthin M, Welte T, Frolich JC, Neumann KH. Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases. BMJ. 2003;327(7407):147–9. doi: 10.1136/bmj.327.7407.147.PubMedCrossRefGoogle Scholar
  11. 11.
    Svensson M, Gustafsson F, Galatius S, Hildebrandt PR, Atar D. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? J Card Fail. 2004;10(4):297–303. doi: 10.1016/j.cardfail.2003.10.012.PubMedCrossRefGoogle Scholar
  12. 12.
    Ramadan FH, Masoodi N, El-Solh AA. Clinical factors associated with hyperkalemia in patients with congestive heart failure. J Clin Pharm Ther. 2005;30(7):233–9. doi: 10.1111/j.1365-2710.2005.00638.x.PubMedCrossRefGoogle Scholar
  13. 13.
    Chan LN, Horn JR. Management of metabolic drug interactions. In: Carter BL, Lake KD, Raebel MA, Bertch KE, Israel MK, Jermain DM, et al., editors. Pharmacotherapy Self-Assessment Program (PSAP). 3rd ed. Module 8. USA: ACCP; 2000. p. 102.Google Scholar
  14. 14.
    Hansten PD, Horn JR. Managing clinically important drug interactions. USA: Wolter Kluwer Health, Inc; 2005.Google Scholar
  15. 15.
    Lacy CF, Armstrong LL, Goldman MP, Lance LL. Drug information handbook international. 14th ed. Hudson, Ohlo: Lexi-Comp Inc; 2006.Google Scholar
  16. 16.
    British National Formulary (BNF). Britain, R. P. S. O. G. 54th ed. London: BMJ Publishing Group Ltd and RPS Publishing; 2007.Google Scholar
  17. 17.
    Field A. Discovering statistics using SPSS. London: SAGE Publications Ltd; 2005. p. 208.Google Scholar
  18. 18.
    Hosmer DW, Taber S, Lemeshow S. The importance of assessing the fit of logistic regression models: a case study. Am J Public Health. 1991;81(12):1630–5.PubMedCrossRefGoogle Scholar
  19. 19.
    Obialo CI, Ofili EO, Mirza T. Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease. Am J Cardiol. 2002;90:663–5. doi: 10.1016/S0002-9149(02)02581-X.PubMedCrossRefGoogle Scholar
  20. 20.
    Tamirisa KP, Aaronson KD, Koelling TM. Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure. Am Heart J. 2004;148:971–8. doi: 10.1016/j.ahj.2004.10.005.PubMedCrossRefGoogle Scholar
  21. 21.
    Reardon LC, Macpherson DS. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors: how much should we worry? Arch Intern Med. 1998;158:26–32. doi: 10.1001/archinte.158.1.26.PubMedCrossRefGoogle Scholar
  22. 22.
    Shah KB, Rao K, Sawyer R, Gottlieb SS. The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure. J Am Coll Cardiol. 2005;46:845–9. doi: 10.1016/j.jacc.2005.06.010.PubMedCrossRefGoogle Scholar
  23. 23.
    Schepkens H, Vanholder R, Billiouw J, Lameire N. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med. 2001;110(6):438–41. doi: 10.1016/S0002-9343(01)00642-8.PubMedCrossRefGoogle Scholar
  24. 24.
    Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The Effect of spironolactone on morbidity and mortality in patients with severe heart failure (RALES). N Engl J Med. 1999;341:709–17. doi: 10.1056/NEJM199909023411001.PubMedCrossRefGoogle Scholar
  25. 25.
    Raebel MA, McClure DL, Chan KA. Laboratory evaluation of potassium and creatinine among ambulatory patients prescribed spironolactone: are we monitoring for hyperkalemia? Ann Pharmacother. 2007;41(2):193–200. doi: 10.1345/aph.1H520.PubMedCrossRefGoogle Scholar
  26. 26.
    Stevens M, Dunlay R. Hyperkalemia in hospitalized patients. Int Urol Nephrol. 2000;32(2):177–80. doi: 10.1023/A:1007135517950.PubMedCrossRefGoogle Scholar
  27. 27.
    De Denus S, Tardif J, White M, Bourassa MG, Racine N, Levesque S, et al. Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction: a retrospective analysis of the studies of left ventricular dysfunction (SOLVD) trials. Am Heart J. 2006;152(4):705–12. doi: 10.1016/j.ahj.2006.05.030.PubMedCrossRefGoogle Scholar
  28. 28.
    Horn H. Hyperkalemia due to drug interactions. Pharm Times. 2004; www.hanstenandhorn.com. Accessed 28 Aug 2008.
  29. 29.
    Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2003;57(1):6–14. doi: 10.1046/j.1365-2125.2003.02007.x.CrossRefGoogle Scholar
  30. 30.
    Bates DW, Miller EB, Cullen DJ, Burdick L, Williams L, Laird N, et al. Patient risk factors for adverse drug events in hospitalized patients. Arch Intern Med. 1999;159(21):2553–60. doi: 10.1001/archinte.159.21.2553.PubMedCrossRefGoogle Scholar
  31. 31.
    Bente G, Stig EA, Kim D. Drug-drug interactions among recently hospitalised patients—frequent but mostly clinically insignificant. Eur J Clin Pharmacol. 2005;61(9):675–81. doi: 10.1007/s00228-005-0978-6.CrossRefGoogle Scholar
  32. 32.
    Ramsay L, Tucker GT. Drugs and the elderly. BMJ. 1981;282:125–7.PubMedCrossRefGoogle Scholar
  33. 33.
    Butler JV, McAvoy H, McEnroy D, Mulkerrin EC. Spironolactone therapy in older patients—the impact of renal dysfunction. Arch Gerontol Geriatr. 2002;35(1):45–9. doi: 10.1016/S0167-4943(01)00214-X.PubMedCrossRefGoogle Scholar
  34. 34.
    Hay E, Derazon H, Bukish N, Katz L, Kruglyakov I, Armoni M. Fatal hyperkalemia related to combined therapy with a COX-2 inhibitor, ACE inhibitor and potassium rich diet. J Emerg Med. 2002;22:349–52. doi: 10.1016/S0736-4679(02)00434-1.PubMedCrossRefGoogle Scholar
  35. 35.
    Wannamethee SG, Lever AF, Shaper AG, Whincup PH. Serum potassium, cigarette smoking, and mortality in middle-aged Men. Am J Epidemiol. 1997;145(7):598–606.PubMedGoogle Scholar
  36. 36.
    Orth SR. Smoking and the kidney. J Am Soc Nephrol. 2002;13(6):1663–72. doi: 10.1097/01.ASN.0000018401.82863.FD.PubMedCrossRefGoogle Scholar
  37. 37.
    Paice B, Gray JM, McBride D, Donnelly T, Lawson DH. Hyperkalaemia in patients in hospital. BMJ. 1983;286(6372):1189–92.PubMedCrossRefGoogle Scholar
  38. 38.
    Hu Y, Carpenter JP, Cheung AT. Life-threatening hyperkalemia: a complication of spironolactone for heart failure in a patient with renal insufficiency. Anesth Analg. 2002;95(1):39–41. doi: 10.1097/00000539-200207000-00006.PubMedCrossRefGoogle Scholar
  39. 39.
    Weiner D, Wingo C. Hyperkalemia: a potential silent killer. J Am Soc Nephrol. 1998;9:1535–43.PubMedGoogle Scholar
  40. 40.
    Gurwitz JH, Field TS, Judge J, Rochon P, Harrold LR, Cadoret C, et al. The incidence of adverse drug events in two large academic long-term care facilities. Am J Med. 2005;118(3):251–8. doi: 10.1016/j.amjmed.2004.09.018.PubMedCrossRefGoogle Scholar
  41. 41.
    Heininger-Rothbucher D, Bischinger S, Ulmer H, Pechlaner C, Speer G, Wiedermann CJ. Incidence and risk of potential adverse drug interactions in the emergency room. Resuscitation. 2001;49(3):283–8. doi: 10.1016/S0300-9572(00)00363-4.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2009

Authors and Affiliations

  • Omalhassan Amir
    • 1
  • Yahaya Hassan
    • 1
    Email author
  • Azmi Sarriff
    • 1
  • Ahmed Awaisu
    • 1
  • Noorizan Abd. Aziz
    • 1
  • Omar Ismail
    • 2
  1. 1.Department of Clinical Pharmacy, School of Pharmaceutical SciencesUniversiti Sains MalaysiaPenangMalaysia
  2. 2.Department of CardiologyPenang General HospitalPenangMalaysia

Personalised recommendations